Therefore, an emerging therapeutic angle in RMS is the use of multi-receptor tyrosine kinase inhibitors (MRTKIs), an important class of agents, many of which are licensed for adult indications and explored in the clinic in sarcoma patients including children and young adults (14, 15). The gene discussed is NTRK1; the disease is sarcoma.